Johnson & Johnson gets atrial fibrillation technology in $63 million deal
This article was originally published in Clinica
Johnson & Johnson has bought Atrionix, which is developing a catheter-based system for the treatment of atrial fibrillation (AF), for $62.8 million in cash.
You may also be interested in...
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.